Gian Life Care Limited

Healthcare — Diagnostics & Research · BSE

₹4.54+₹0.01 (+0.22%)

DalalBaazaar Score

36 / 100

🔴 Weak

Verdict

CAUTION

Risk

High

Driven by the company is currently loss-making, micro-cap size, which brings thin liquidity, falling profits.

In simple words: The company is currently losing money, but sales are shrinking. The direction of profits is the main factor to watch.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 7:02 pm

Understanding the Business

Company site ↗

The 60-second version of Gian Life Care Limited — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Gian Life Care Limited provides diagnostic and related healthcare tests and services primarily in India. It offers patient diagnosis, as well as prevention and wellness diagnosis services.

IndustryDiagnostics & Research

SectorHealthcare

Employees24

Annual revenue₹7 Cr

How does it make money?

Turns over ₹7 Cr a year. Of every ₹100 of sales, about ₹-1 reaches shareholders as profit, with ₹20 left at the operating level before interest, tax and depreciation. Each of its 24 employees supports ₹27.6 lakh of revenue a year, the signature of a people-led business.

Revenue / employee₹27.6 lakh

Who are its competitors?

The closest listed comparisons in its industry are SUN PHARMACEUTICAL IND L, CIPLA LTD, DR. REDDY S LABORATORIES, APOLLO HOSPITALS ENTER. L. These are the companies its valuation and returns are measured against elsewhere in this report.

Compared side by side in Peers ↓

What is its competitive advantage?Little sign of one

Returns on capital of 2.4% are at or below what the capital likely costs. That is the financial pattern of a business competing largely on price, where advantage has to come from execution rather than position.

Peer median ROE14.5%

What has been driving growth?

Profit has moved mainly because margins changed, not because the business sold much more. Over 3 years revenue moved -58% while net margin moved -102% relative to itself. What this cannot tell you is which products, customers or geographies did the work — that lives in the segment disclosures of the annual report.

Revenue effect-58%

Margin effect-102%

DalalBaazaar Score

36/ 100

Weak

Weighted across six categories. Every point is explained below.

✗ Revenue has contracted at 25.3% a year
✗ Profit fell 70.6% in the latest year

Quality vs. Valuation

Company Quality

32/ 100

Weak

How good the business is, ignoring the share price entirely.

Valuation

54/ 100

Fair

What you are being asked to pay, ignoring how good the business is.

Weak on business quality and not cheap enough to compensate.

vs. its own history

Not enough price and earnings history

vs. sector peers

Not enough peers with a usable P/E

vs. generic bands

N/A

No P/E — the company is lossmaking

EV/EBITDA

2.7x

PEG

—

What's Good / What's Bad

🟢 What's Going Well0

Nothing stands out as clearly improving on the years of data available.

🔴 What Needs Attention2

Return on equity is falling
ROE has dropped from 31.2% to -0.2% — each rupee of shareholder capital earns less than it did.
Return on capital is falling
ROCE has declined from 38.4% to 2.4% — often a sign of competition or overexpansion.

Red Flags

6 items require attention · 4 high · 2 watch

🔴Thin interest coverageFinancial
Operating profit covers interest only 1.1x — little room if earnings dip.
🔴The company is lossmakingFinancial
Net profit of -₹0 Cr in the latest reported year.
🔴Significant margin compressionFinancial
EBITDA margin has fallen 21.2 points, from 41.0% to 19.8%.
🔴Receivables growing faster than salesFinancial
Receivables up 243% against revenue up -58% — sales are being booked faster than they are collected.
🟡Debt is increasingFinancial
Total debt is up 29% over 3 years.
🟡Interest coverage is deterioratingFinancial
Cover has fallen from 13.4x to 1.1x.

Investment Thesis

🟢 Bull CaseWhat could make this work?

Self-funding with balance-sheet headroom
Positive free cash flow of ₹0 Cr alongside low debt means growth, buybacks or dividends need no outside money — and a downturn can be absorbed rather than refinanced.

🔴 Bear CaseWhat could go wrong?

Margins are being competed away
EBITDA margin has fallen from 41.0% to 19.8%. If the trend continues, profit falls even on flat sales — and margin decline rarely reverses quickly.
The debt load needs earnings to hold up
Debt is 4.5x EBITDA. At that level a downturn in earnings turns a manageable balance sheet into a refinancing problem, and lenders get paid before shareholders.
Sales are being booked faster than collected
Receivables are up 243% against revenue up -58%. If customers keep taking longer to pay, reported profit will not turn into cash — and write-offs follow if some never do.
Returns on shareholder capital are falling
ROE has dropped from 31.2% to -0.2%. Each rupee of equity earns less than it did, so profit growth increasingly depends on raising more capital rather than on the existing base working harder.
Earnings are hard to forecast
Profit has swung sharply from year to year, so any single year — good or bad — is a weak guide to the next. Cyclical earnings deserve lower multiples for that reason.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1EBITDA margin holds above 18%✓ 19.8%
Two points below today's level — enough room for noise, tight enough to catch real compression.
2Debt / EBITDA falls below 3x✗ 4.5x
Already stretched, so this is a reduction target rather than a level to hold. Around 3x is where lenders typically start attaching conditions.
3Interest cover stays above 3x✗ 1.1x
How much operating profit can fall before interest stops being comfortably covered.
4Free cash flow remains positive✓ ₹0 Cr
Profit that never becomes cash eventually stops being profit.
5ROCE stays above 8%✗ 2.4%
Falling returns on capital are usually competition arriving, and show up here before they reach the margin.

Investment Checklist

5 / 11 checks passed

✗ Strong return on equity (ROE ≥ 15%)
✗ Strong return on capital employed (ROCE ≥ 15%)
✗ Healthy net margin (≥ 10%)
✓ Generates positive free cash flow
✓ Manageable leverage (Debt/Equity < 1.0)
✓ Adequate short-term liquidity (Current Ratio ≥ 1.0)
✗ Revenue growing year-over-year
✗ Profit growing year-over-year
✓ Not trading at an extreme valuation (P/E < 40x)
✓ Not buying right at the 52-week high
✗ Short-term technical trend isn't bearish

Price history

Quick Metrics

3 good · 2 neutral · 6 weak

Market Cap

₹5 Cr

Micro Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

Not meaningful

Loss-making

Earnings are negative, so a P/E multiple can't be read here

P/B Ratio

0.25x

Reasonable

Reasonable against the company's book value

EPS (TTM)

₹-0.94

Loss-making

Negative earnings per share — the business is losing money

ROE

-0.2%

Weak

Weak capital efficiency

ROCE

2.4%

Weak

Low return on total capital employed

Debt/Equity

0.31x

Low

Conservative leverage

Revenue Growth (YoY)

-29.3%

Shrinking

Sales are contracting

Profit Growth (YoY)

-70.6%

Falling

Profits are shrinking

Dividend Yield

None

No dividend yield reported — usually means no payout, but verify if one was recently initiated

Free Cash Flow

₹0 Cr

Cash generative

Generates cash even after funding its capex

More Metrics

Operating Margin

12.2%

Average

Average margins

Net Margin

-25.3%

Weak

Very little revenue reaches the bottom line

Current Ratio

1.45

Comfortable

Healthy short-term liquidity

Beta (vs Nifty)

0.09

Defensive

Steadier than the market

52W Range Position

Near low

Near its 52-week low

Technical Snapshot

SMA 20 / SMA 50

4.6 / 4.7

Bearish alignment (short < long)

Price vs SMA 200

Below

Long-term downtrend

RSI (14)

43.7

Neutral momentum

Financial Trend (4-Year)

Metric	FY22	FY23	FY24	FY25	3Y CAGR
Revenue	₹16 Cr	₹12 Cr	₹13 Cr	₹7 Cr	-25.3%
EBITDA	₹7 Cr	₹3 Cr	₹7 Cr	₹1 Cr	-41.4%
EBITDA Margin	41.0%	21.1%	51.7%	19.8%	—
PAT (Net Profit)	₹4 Cr	₹1 Cr	₹4 Cr	-₹0 Cr	—
EPS	₹4.23	₹1.03	₹4.01	₹-0.04	—
ROE	31.2%	7.0%	21.6%	-0.2%	—
ROCE	38.4%	11.6%	27.5%	2.4%	—
Total Debt	₹5 Cr	₹5 Cr	₹5 Cr	₹6 Cr	+9.0%
Free Cash Flow	₹0 Cr	₹1 Cr	-₹0 Cr	₹0 Cr	-10.8%

🔴 Revenue has shrunk at 25.3% a year over 3 years.

🔴 EBITDA has shrunk at 41.4% a year over 3 years.

🔴 EBITDA Margin has fallen from 41.0% to 19.8% over 3 years (-21.2 pts).

🔴 PAT (Net Profit) has turned negative, from ₹4 Cr to -₹0 Cr.

🔴 EPS has turned negative, from ₹4.23 to ₹-0.04.

🔴 ROE has fallen from 31.2% to -0.2% over 3 years (-31.4 pts).

🔴 ROCE has fallen from 38.4% to 2.4% over 3 years (-36.0 pts).

🔴 Total Debt has grown at 9.0% a year over 3 years.

🔴 Free Cash Flow has shrunk at 10.8% a year over 3 years.

Balance Sheet & Cash Flow — FY2025

Total Assets

₹36 Cr

Total Liabilities

₹17 Cr

Cash & Equivalents

₹7 Cr

Operating Cash Flow

₹0 Cr

Capex

-₹0 Cr

Shareholding (proxy)

Institutional Holding

0.0%

Insider Holding

54.0%

Peer Comparison

Company	P/E	ROE
SUN PHARMACEUTICAL IND L	34.9x	14.5%
CIPLA LTD	31.8x	9.8%
DR. REDDY S LABORATORIES	31.0x	8.8%
APOLLO HOSPITALS ENTER. L	54.3x	22.0%

Recent News

2 mixed4 general

Markets Rise, But Gian Lifecare Ltd Slides to All-Time Low Amid Stock-Specific Sell-Off

MarketsMojo, 18 Oct

Gian Life Care Ltd. Shareholding Pattern – Promoters, FIIs & DIIs

Value Research, 27 Aug

Gian Life Care Limited Reports Q3FY26 Results with Auditor Concerns Over Cash Balance

scanx.trade, 14 FebResults

🟡Mixed / dependsA results event. The figures on this page update once the new statements reach the data feed, which usually lags the announcement.

Gian Life Care Ltd. Financials – Balance Sheet, Profit & Loss, Cash Flow

Value Research, 28 Aug

MDRC Stock Price and Chart — BSE:MDRC

TradingView, 07 Jan

Q3 results 2026: Eternal, Dr Reddy’s, HPCL to Bank of India - 57 companies to declare earnings today; check full list

Livemint, 21 JanResults

🟡Mixed / dependsA results event. The figures on this page update once the new statements reach the data feed, which usually lags the announcement.

Watch Items

Revenue growth is negative (-29.3%) on the latest reported period — check if this is one-off or a trend.
Trading very close to its 52-week low — worth checking whether this reflects a temporary setback or a structural problem.
Cross-check against the company's latest quarterly filing / investor presentation before acting.

DalalBaazaar Thesis

MiddlingFinancial Health · Valuation

WeakBusiness Quality · Growth · Profitability · Risk

Points for each in the Score ↑

Weak on the fundamentals

Poor scores on business quality without a price low enough to compensate. There is no obvious argument for owning this over a stronger company at a similar valuation. 4 high-severity red flags sit above this conclusion and should be read first.

3 of 5 tripwires tripped — Debt / EBITDA falls below 3x; Interest cover stays above 3x; ROCE stays above 8% · see Key things to watch ↑